Sleep Treatments | Sleep Review
The Sleep Research Society hosted an online focus group of more than a dozen sleep experts, including sleep medicine and dental sleep medicine specialists, to discuss alternative non-CPAP treatment alternatives for obstructive sleep apnea. Moderated by Sairam Parthasarathy, MD, FAASM, the topic is particularly timely due to the scarcity of CPAP equipment caused in part by Philips’ CPAP / bilevel recall.
“This is a timely and important discussion about the true positioning of non-PAP treatment alternatives and the implementation aspects of such therapies,” said Parthasarathy, who serves on the board of the Sleep Research Society and president of the Sleep Research Society Foundation, in a publication.
The two-hour webinar, available on the Sleep Research Society’s YouTube channel, features conversations on topics such as:
- Threshold of treatment failure and when to consider alternative therapies;
- whether non-CPAP therapies should be offered as first-line therapies;
- provisional oral appliances as a way of predicting the response to custom oral appliances;
- closed multidisciplinary referral systems to dentists for oral devices and ENT surgeons who implant hyperglossal nerve stimulation; and
- Precision Sleep Medicine.
The mouthpiece manufacturer SomnoMed sponsored the webinar as part of its medical initiative.
With growing awareness of the challenges of patient compliance in PAP therapy for long-term OSA treatment success, SomnoMed is forced to advance the discussion about the significant potential of OAT in providing effective lifelong OSA treatment for millions of people with OSA that would otherwise likely go untreated, “says Neil Verdal-Austin, CEO of SomnoMed, in a press release. “Our partnership with the Sleep Research Society will help bring these discussions to the fore and treat more patients more effectively.”
Matt Conlon, EVP of SomnoMed North America, said in a press release: “OAT is the treatment of a serious condition with dental therapy. Treatment partner or “SomnoMed’s medical initiative is driving these patient-centered collaborations so that we can use the strong scientific evidence that exists today and that supports greater acceptance of OAT.”